Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
08-Jul-2026 | 599 | 609.95 | 588.1 | 595.35 | 27,838 | 42,01,86,875.35 | 3,19,408 |
09-Jul-2026 | 599 | 632.8 | 595.4 | 622.3 | 43,291 | 83,44,65,269.55 | 5,65,578 |
10-Jul-2026 | 624.75 | 633.3 | 617.15 | 627.15 | 22,300 | 38,48,56,243.2 | 2,89,522 |
13-Jul-2026 | 624.05 | 634 | 615.85 | 630.2 | 13,657 | 24,04,37,062.9 | 1,90,008 |
14-Jul-2026 | 630 | 650 | 622 | 624.25 | 25,470 | 60,85,48,852.1 | 4,87,806 |
15-Jul-2026 | 629.9 | 648 | 628.05 | 645.75 | 22,002 | 47,45,14,068.85 | 3,71,115 |
16-Jul-2026 | 644.9 | 644.9 | 630.5 | 637.85 | 16,651 | 24,75,22,385.4 | 1,66,418 |
17-Jul-2026 | 635 | 638 | 617.1 | 620.25 | 22,450 | 30,13,86,603.7 | 2,46,500 |
20-Jul-2026 | 620.8 | 636.25 | 618.1 | 625.45 | 18,396 | 26,03,31,706.25 | 1,98,918 |
21-Jul-2026 | 630 | 642 | 615.2 | 640 | 15,958 | 32,19,55,267.65 | 2,50,482 |
22-Jul-2026 | 639.8 | 640 | 610.95 | 613.35 | 24,047 | 33,70,04,065.75 | 2,44,927 |
23-Jul-2026 | 609 | 624.4 | 601 | 603.6 | 18,280 | 29,45,59,656.2 | 2,28,365 |
24-Jul-2026 | 601 | 614.45 | 597.5 | 606.2 | 17,033 | 25,67,86,878.9 | 1,58,729 |
27-Jul-2026 | 615 | 626.5 | 607.1 | 620.6 | 14,644 | 18,97,20,719.65 | 1,30,857 |
28-Jul-2026 | 625 | 625.25 | 600.55 | 605.2 | 16,356 | 26,40,88,875.1 | 2,03,532 |
29-Jul-2026 | 612 | 616.3 | 600.1 | 604.6 | 17,851 | 23,19,66,215.15 | 1,76,052 |
30-Jul-2026 | 606.9 | 613.35 | 601 | 602.95 | 9,548 | 14,70,65,208.75 | 1,27,443 |
31-Jul-2026 | 604.4 | 614.95 | 601.15 | 611.25 | 16,239 | 29,65,85,858 | 2,50,969 |
03-Aug-2026 | 616.1 | 629.75 | 614.1 | 623.55 | 16,867 | 29,70,84,842.8 | 2,43,753 |
04-Aug-2026 | 622.95 | 655.75 | 621.25 | 644.65 | 41,335 | 92,77,67,335.3 | 6,40,493 |
05-Aug-2026 | 650 | 753.85 | 636.85 | 721.75 | 3,30,779 | 11,85,75,04,536.4 | 21,55,105 |
06-Aug-2026 | 739.1 | 786.15 | 730.3 | 738.8 | 4,00,191 | 15,73,95,02,236.25 | 24,94,959 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
